On July 14, the Office of National Drug Control Policy issued a notice rescheduling the commission’s report meant to detail a federal strategy to combat the epidemic. The report, scheduled to be delivered via conference call on Monday, was rescheduled for July 31.
Bertha Madras, PhD, a professor of psychobiology at Harvard Medical School in Boston and a member of the opioid commission, told CBS News the delayed report was “trivial compared to the magnitude of the problems and types of solutions needed to formulate an effective response [to the opioid epidemic].”
“The surgeon general’s report came out in 2016 after the ravages were present for eight years. [T]he Comprehensive Addiction and Recovery Act came out after the ravages were present for eight years,” Dr. Madras told CBS News. “That’s really the story that should be pursued.”
When President Donald Trump signed an executive order in March to create the special commission, the panel was given an initial deadline of 90 days to issue a report.
More articles on opioids:
Ohio AG allocates $3M to fund opioid response teams
Study: 80% of Mayo Clinic opioid prescriptions exceed upcoming prescribing guidelines
1 in 3 Medicare Part D beneficiaries received opioids in 2016, finds OIG
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
